Why Insmed (INSM) Stock Is Up Today

NEW YORK (TheStreet) -- Insmed  (INSM) rose Tuesday after the biopharmaceutical company announced data from its Phase 2 clinical trial of ARIKAYCE in treating resistant nontuberculous mycobacterial lung infections.

The company revealed 78 of the 80 patients agreed to receive once-daily ARIKAYCE in addition to standard of care treatment for an additional 84 days at the conclusion of the double blind phase of the trial. Data from 68 of these patients were available for the poster at the American Thoracic Society, where Insmed presented the data Tuesday, and 21 of these patients were culture negative for NTM at Day 168.

Piper Jaffray said the data was in line with expectations and noted specialists around the poster were "extremely enthusiastic." The firm reiterated its "overweight" rating on the stock.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 8.56% to $14.21 at 2:34 p.m.

INSM Chart

INSM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

North Korea Gives Wall Street Rude Awakening After Labor Day Break

Dow Tanks, Fear Gauge Spikes as United Tech Slumps, North Korea Rattles Nerves

North Korea Threat Roars Back Into Focus and Wall Street Retreats

Stock Futures Decline Amid Rising North Korea Tensions

Health Sector Down As Report of Industry Price Collusion Surfaces